Research
Hormonal
Tirzepatide improves kidney function markers (eGFR decline and albuminuria) and may slow the progression of chronic kidney disease in patients with type 2 diabetes.
Tirzepatide may help protect your kidneys by slowing the decline in kidney function and reducing protein in the urine, which is beneficial for long-term kidney health in diabetes.
GoodSupportsMEDIUM confidence
V post-hoc analýze výsledků této studie bylo navíc zjištěno, že u pacientů s DM2 ve vysokém kardiovaskulárním riziku vede léčba tirzepatidem ke zpomalení rychlosti poklesu odhadované glomerální filtrace (eGFR) a snížení albuminurie (UACR) v porovnání s inzulinem glargin.
Why this rating
Based on post-hoc analysis of Phase 3 trial (SURPASS 4), not primary endpoint.
Source
Tirzepatide - a promising medication for cardiovascular protection and treatment of Type 2 diabetes and obesity
Pavlína Piťhová · Vnitřní lékařství · 2025
DOI 10.36290/vnl.2025.009
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GLP-1/GIP receptor agonist administered once weekly, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity compared to placebo and other active comparators.Strong
- Tirzepatide provides cardiovascular protection by reducing major adverse cardiovascular events (MACE) and improving cardiovascular risk scores in patients with type 2 diabetes and obesity.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →